Antituberculosis medication

The Idaho Department of Health and Welfare is soliciting bids for Invitation to Bid (ITB) No. 538 to procure antituberculosis medications for public health districts, TB clinics, and healthcare providers across multiple Idaho counties, including Kootenai County. The procurement seeks various medications for treating drug-susceptible and drug-resistant tuberculosis, including Amikacin, Ethambutol, Isoniazid, Levofloxacin, Linezolid, Moxifloxacin, Pyrazinamide, Pyridoxine, Rifampin, and Rifapentine. Vendors must provide a comprehensive solution that includes direct medication delivery, maintenance of a 24/7 functional ordering website, and the ability to drop-ship medications to various healthcare providers. The initial contract term is one year, with potential renewals up to five years upon mutual agreement, and the award will be made on an "all or none" basis to the responsive, responsible bidder offering the lowest total cost. Bids are due by July 22, 2024, and the successful contractor must provide pricing with no additional shipping costs and maintain adequate inventory levels for high-volume medications.

No specific set-aside designations or restrictions for disadvantaged enterprises were explicitly identified in the documentation. The solicitation appears open to all qualified vendors who can meet the technical specifications and insurance requirements. The contract includes a 1.25% administrative fee and requires vendors to maintain comprehensive insurance coverage, including commercial general liability, commercial automobile liability, and workers' compensation. While no incumbent vendor information was provided, the estimated annual contract value suggests a significant procurement opportunity. Vendors must provide a fully burdened total cost, demonstrate the ability to subcontract if necessary (while maintaining full responsibility for deliverables), and be prepared to justify any potential price changes with 45-day advance written documentation. The contract allows for potential price adjustments after the first year, subject to mutual agreement and verifiable cost increases.